p.49 抽出テキスト

September 10, 2019 Circulation. 2019;140:e596–e646. DOI: 10.1161/CIR.0000000000000678 e644

CLINICAL STATEMENTS AND GUIDELINES Arnett et al 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

Eileen M. Handberg Content Reviewer—ACC Research Professor of

Medicine; Director, Clinical Trials Program; Program Director, Florida CARES, UF Health •  Bristol-Myers Squibb Company None None •  Aastrom Biosciences* •  Amorcyte, Inc* •  Biocardia, Inc* •  Brigham and Women’s Hospital* •  Capricor* •  Cytori Therapeutics, Inc.* •  Department of Defense* •  Direct Flow Medical* •  Duke Clinical Research Institute* •  East Carolina University* •  Everyfit Inc* •  MEDTRONIC* •  Merck & Co., Inc.* •  Mesoblast Inc* •  NIH* •  PCORI* •  Sanofi Aventis* •  Amgen (Other) •  AstraZeneca (Other) •  Boehringer Ingelheim (Other) •  Daiichi Sankyo (Other) •  Gilead Sciences, Inc. (Other) •  Ionis (Other) •  Relypsa (Other) None None

Prem Soman Content Reviewer—ACC Associate Professor

of Medicine (Cardiology), Director, Nuclear Cardiology,

UPMC •  Alnylam Pharma None •  American Society of Nuclear Cardiology* •  Astellas Pharma US* None None None

Eric Stecker Content Reviewer—ACC Associate Professor of Medicine, Division

of Cardiovascular Medicine School of Medicine, OHSU None None •  Hygeia / Desi MD* •  American Heart Association* •  Medical Research Foundation of Oregon* None None None

Pamela Morris Content Reviewer—ACC Professor, Medical University of South

Carolina •  Amgen Inc. •  Sanofi •  Regeneron None None None None None None

Andrew Freeman Content Reviewer—ACC Director, Clinical

Cardiology and Operations; Co- Director, Nuclear Cardiology, National

Jewish Health None •  Boehringer Ingelheim* None None None None None

Carl J. Lavie Content Reviewer—ACC Medical Director, Cardiac Rehabilitation

and Prevention, Ochsner Clinic Foundation None •  Amgen* •  ER Squibb & Sons •  Pfizer* •  Aralez Pharmaceuticals •  Amarin Pharma •  Sanofi Aventis* None None None None None

James Stein Content Reviewer—ACC Director, UW Health Preventive Cardiology

Program, Robert Turell Professor in Cardiovascular Research, UW School

of Medicine and Public Health •  Eli Lilly and Company (DSMB) None None None •  Up To Date (Other) •  Wisconsin Alumni Research Foundation (Other) None None

Heather Johnson Content Reviewer—ACC Associate Professor

in the Division of Cardiovascular Medicine at the University of Wisconsin School of Medicine and Public

Health None None None None •  Pfizer None None

Nanette Wenger Content Reviewer—ACC Professor of Medicine, Division of Cardiology,

Emory University School of Medicine •  Janssen Pharmaceuticals, Inc* •  Amgen •  AstraZeneca •  Gilead Sciences •  Merck None None •  Gilead Sciences* •  NHLBI* •  Pfizer* •  Society for Women’s Health Research* None None None

Appendix 3.  Continued

Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/

Principal Personal Research Institutional, Organizational,

or Other Financial Benefit Expert Witness Salary

(Continued )

Downloaded from http://ahajournals.org by on October 7, 2026